Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5533149 | 0.92 | CD44 (0.56) | CD44KDM4EKMT2AMEN1TDP1 | |
| SCHEMBL30515968 | 0.84 | CD44 (0.56) | CD44TDP1CYP3A4GAAMAPT | |
| SCHEMBL5952534 | 0.84 | CD44 (0.56) | CD44KDM4EKMT2ATDP1CYP3A4 | |
| SCHEMBL17030863 | 0.84 | CD44 (0.56) | CD44TDP1CYP3A4GAAMAPT | |
| SCHEMBL974647 | 0.83 | KDM4E (0.52) | KDM4EKMT2AMEN1TDP1CYP3A4 | |
| SCHEMBL4628056 | 0.83 | SORT1 (0.46) | KDM4EKMT2AMEN1TDP1ALDH1A1 | |
| SCHEMBL3031603 | 0.83 | CYP3A4 (0.52) | KDM4EKMT2AMEN1TDP1CYP3A4 | |
| SCHEMBL30079667 | 0.83 | KDM4E (0.52) | KDM4EKMT2AMEN1TDP1CYP3A4 | |
| SCHEMBL5240171 | 0.82 | CD44 (0.48) | CD44KDM4EKMT2AMEN1TDP1 | |
| SCHEMBL2892593 | 0.81 | GABRP (0.52) | KDM4EKMT2AMEN1TDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021252475-A1 | QUINAZOLINE DERIVATIVES USEFUL AS SELECTIVE HDAC6 INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2021-12-16 | — | — | WO | disclosed |
| EP-2842939-B1 | BENZAMIDE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-2842939-B1 | BENZAMIDE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-9695118-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-07-04 | — | — | US | disclosed |
| US-9695118-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-07-04 | — | — | US | disclosed |
| US-9695118-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-07-04 | — | — | US | disclosed |
| US-9567304-B2 | Quinazolinedione derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-02-14 | — | — | US | disclosed |
| US-9567304-B2 | Quinazolinedione derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-02-14 | — | — | US | disclosed |
| EP-2842946-A1 | QUINAZOLINEDIONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-03-04 | — | — | EP | disclosed |
| WO-2013161853-A1 | QUINAZOLINEDIONE DERIVATIVE | 中外製薬株式会社 (JP) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013161851-A1 | BENZAMIDE DERIVATIVE | 中外製薬株式会社 (JP) | 2013-10-31 | — | — | WO | disclosed |
| EP-1155012-B1 | ANTI-CANCER DIHYDROQUINAZOLINE DERIVATIVES | CANCER REC TECH LTD (GB) | 2004-04-14 | — | — | EP | disclosed |
| US-6699861-B1 | ANTI-CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-03-02 | — | — | US | disclosed |
| WO-2003106435-A1 | FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF | SANKYO COMPANY, LIMITED (JP) | 2003-12-24 | — | — | WO | disclosed |
| EP-1155012-A1 | ANTI-CANCER DIHYDROQUINAZOLINE DERIVATIVES | Cancer Research Ventures Limited (GB) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050417-A1 | ANTI-CANCER DIHYDROQUINAZOLINE DERIVATIVES | CANCER RESEARCH VENTURES LIMITED (GB) | 2000-08-31 | — | — | WO | disclosed |
| CN-1235992-A | Water-soluble fiber-reactive dyes, processes for their preparation and their use | HOECHST AG (DE) | 1999-11-24 | — | — | CN | disclosed |
| CN-1108277-A | Water-soluble fibre-reactive dyes, their preparation and their use | HOECHST AG (DE) | 1995-09-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CD44 4800/4885KDM4E 3221/4885KMT2A 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.